{"url_path":"/sec/arvn/8-k/2026-06-22/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-22","source_url":"https://www.sec.gov/Archives/edgar/data/1655759/0001628280-26-044627-index.html","accession_number":"0001628280-26-044627","cik":"0001655759","ticker":"ARVN","issuer_name":"ARVINAS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1655759/0001628280-26-044627-index.html","primary_entity_key":"0001655759","primary_entity_name":"ARVINAS, INC."},"word_count":418,"has_tables":true,"body_markdown":"Item 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\nOn June 22, 2026, Arvinas, Inc., a Delaware corporation (the “Company”), and Noah Berkowitz, M.D., Ph.D., the Company’s chief medical officer, agreed that Dr. Berkowitz would depart from his employment with the Company, effective July 3, 2026 (the “Departure”). The Company expects that Dr. Berkowitz will remain as chief medical officer of the Company through July 3, 2026 before leaving to pursue other opportunities. The Company has begun a search to find a new chief medical officer to replace Dr. Berkowitz.\n\nIn connection with his Departure, on June 22, 2026, the Company and Dr. Berkowitz entered into a separation agreement and release of claims (the “Separation Agreement”), which includes a release of claims by Dr. Berkowitz in the Company’s favor, Dr. Berkowitz’s agreement to continued compliance with the terms of his proprietary information and assignment agreement, as well as confidentiality, cooperation and non-disparagement obligations. Pursuant to the terms of the Separation Agreement, subject to its non-revocation, Dr. Berkowitz will be entitled to certain severance benefits, including: (1) continued payment of his base salary for a period of nine months, (2) payment of the portion of health coverage premiums paid for similarly-situated, active employees who receive the same type of coverage, for a period of up to nine months, and (3) the acceleration of vesting of restricted stock units (“RSUs”) that were granted to Dr. Berkowitz by the Company pursuant to the Company’s 2018 Stock Incentive Plan or pursuant to Nasdaq Listing Rule 5635(c), which reflects the acceleration of RSUs granted to Dr. Berkowitz that, by the terms of the applicable award agreement, would vest on or before May 9, 2027. All other RSUs awards not accelerated shall be forfeited in accordance with the terms of the applicable RSU award. The acceleration of vesting is subject to taxation and applicable withholdings.\n\nThe description of the terms of the Separation Agreement contained in this Item 5.02 is qualified in its entirety by reference to the full text of the Separation Agreement, a copy of which the Company expects to file with its Form 10-Q for the quarter ending June 30, 2026, and are incorporated herein by reference.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nARVINAS, INC.\n\nDate: June 22, 2026By:/s/ Jared Freedberg\n\nJared Freedberg\n\nGeneral Counsel"}